Breast cancer cells co-labeled with CD49f+/CD61+ (ITGB3) exhibit enhanced tumor sphere-forming ability, tumorigenicity, and resistance to chemotherapy drugs (Lo et al., 2012). Here, ITGB3 is linked to breast carcinoma.